Literature DB >> 19114862

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.

Sharon L Walmsley1, Kathleen Squires, Laurence Weiss, Philippa Easterbrook, Anna Orani, Michael Kraft, Joseph Scherer.   

Abstract

Gender-related differences in the efficacy and safety of ritonavir-boosted tipranavir [tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)] were evaluated in a subanalysis of the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) trials. Data from HIV-1-infected women (203; TPV/r = 117) and men (1280; TPV/r = 629) showed no significant gender-related differences in HIV RNA response rates (at 48 weeks) and safety (at 96 weeks) despite higher mean steady-state plasma TPV trough concentrations in women. Significantly greater increases in CD4 cell count (+81.2 vs. +48.6; P = 0.0012) were observed in women at week 48.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19114862     DOI： 10.1097/QAD.0b013e3283229f81

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  6 in total

Review 1.  Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Authors:  Babafemi Taiwo; Robert L Murphy; Christine Katlama
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

2.  Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Authors:  Kathleen E Squires; Linda-Gail Bekker; Joseph J Eron; Benjamin Cheng; Juergen K Rockstroh; Farid Marquez; Princy Kumar; Melanie Thompson; Rafael E Campo; Karam Mounzer; Kim M Strohmaier; Chengxing Lu; Anthony Rodgers; Beth E Jackson; Larissa A Wenning; Michael Robertson; Bach-Yen T Nguyen; Peter Sklar
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-26       Impact factor: 2.205

3.  Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

Authors:  Kathleen E Squires; Margaret Johnson; Rong Yang; Jonathan Uy; Louise Sheppard; Judith Absalon; Donnie McGrath
Journal:  J Antimicrob Chemother       Date:  2010-12-09       Impact factor: 5.790

4.  Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

Authors:  Lycely Del C Sepúlveda-Torres; Alexandra De La Rosa; Luz Cumba; Nawal Boukli; Eddy Ríos-Olivares; Luis A Cubano
Journal:  AIDS Res Treat       Date:  2012-04-24

5.  Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.

Authors:  Kathleen E Squires; Benjamin Young; Lizette Santiago; Robin H Dretler; Sharon L Walmsley; Henry H Zhao; Gary E Pakes; Lisa L Ross; Mark S Shaefer
Journal:  HIV AIDS (Auckl)       Date:  2017-03-03

6.  Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.

Authors:  Veronica Svedhem-Johansson; Pascal Pugliese; Norbert H Brockmeyer; Anders Thalme; Claudia Michalik; Stefan Esser; Marie-Helene Barlet; Tina Nakonz; Maria J Jimenez-Exposito
Journal:  Curr HIV Res       Date:  2013-06       Impact factor: 1.581
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.